Cargando…

The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications

Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of NM in inhibiting ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xi, Xu, Zhijie, Zeng, Shuangshuang, Wang, Xiang, Liu, Wanli, Qian, Long, Wei, Jie, Yang, Xue, Shen, Qiuying, Gong, Zhicheng, Yan, Yuanliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733886/
https://www.ncbi.nlm.nih.gov/pubmed/31552177
http://dx.doi.org/10.3389/fonc.2019.00852
_version_ 1783450046864293888
author Chen, Xi
Xu, Zhijie
Zeng, Shuangshuang
Wang, Xiang
Liu, Wanli
Qian, Long
Wei, Jie
Yang, Xue
Shen, Qiuying
Gong, Zhicheng
Yan, Yuanliang
author_facet Chen, Xi
Xu, Zhijie
Zeng, Shuangshuang
Wang, Xiang
Liu, Wanli
Qian, Long
Wei, Jie
Yang, Xue
Shen, Qiuying
Gong, Zhicheng
Yan, Yuanliang
author_sort Chen, Xi
collection PubMed
description Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of NM in inhibiting cancer progression. Alone or in combination treatments, studies have shown that NM attenuates various malignant tumors, including pancreatic, colorectal, gastric, gallbladder, and hepatocellular cancers. In this review, based on several activating pathways, including the canonical Nuclear factor-κB (NF-κB) signaling pathway, tumor necrosis factor receptor-1 (TNFR1) signaling pathway, and tumorigenesis-related tryptase secreted by mast cells, we summarize the anticancer properties of NM in existing studies both in vitro and in vivo. In addition, the efficacy and side effects of NM in cancer patients are summarized in detail. To further clarify NM's antitumor activities, clinical trials devoted to validating the clinical applications and underlying mechanisms are needed in the future.
format Online
Article
Text
id pubmed-6733886
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67338862019-09-24 The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications Chen, Xi Xu, Zhijie Zeng, Shuangshuang Wang, Xiang Liu, Wanli Qian, Long Wei, Jie Yang, Xue Shen, Qiuying Gong, Zhicheng Yan, Yuanliang Front Oncol Oncology Nafamostat mesylate (NM), a synthetic serine protease inhibitor first placed on the market by Japan Tobacco in 1986, has been approved to treat inflammatory-related diseases, such as pancreatitis. Recently, an increasing number of studies have highlighted the promising effects of NM in inhibiting cancer progression. Alone or in combination treatments, studies have shown that NM attenuates various malignant tumors, including pancreatic, colorectal, gastric, gallbladder, and hepatocellular cancers. In this review, based on several activating pathways, including the canonical Nuclear factor-κB (NF-κB) signaling pathway, tumor necrosis factor receptor-1 (TNFR1) signaling pathway, and tumorigenesis-related tryptase secreted by mast cells, we summarize the anticancer properties of NM in existing studies both in vitro and in vivo. In addition, the efficacy and side effects of NM in cancer patients are summarized in detail. To further clarify NM's antitumor activities, clinical trials devoted to validating the clinical applications and underlying mechanisms are needed in the future. Frontiers Media S.A. 2019-09-03 /pmc/articles/PMC6733886/ /pubmed/31552177 http://dx.doi.org/10.3389/fonc.2019.00852 Text en Copyright © 2019 Chen, Xu, Zeng, Wang, Liu, Qian, Wei, Yang, Shen, Gong and Yan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Chen, Xi
Xu, Zhijie
Zeng, Shuangshuang
Wang, Xiang
Liu, Wanli
Qian, Long
Wei, Jie
Yang, Xue
Shen, Qiuying
Gong, Zhicheng
Yan, Yuanliang
The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
title The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
title_full The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
title_fullStr The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
title_full_unstemmed The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
title_short The Molecular Aspect of Antitumor Effects of Protease Inhibitor Nafamostat Mesylate and Its Role in Potential Clinical Applications
title_sort molecular aspect of antitumor effects of protease inhibitor nafamostat mesylate and its role in potential clinical applications
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6733886/
https://www.ncbi.nlm.nih.gov/pubmed/31552177
http://dx.doi.org/10.3389/fonc.2019.00852
work_keys_str_mv AT chenxi themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT xuzhijie themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT zengshuangshuang themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT wangxiang themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT liuwanli themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT qianlong themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT weijie themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT yangxue themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT shenqiuying themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT gongzhicheng themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT yanyuanliang themolecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT chenxi molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT xuzhijie molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT zengshuangshuang molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT wangxiang molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT liuwanli molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT qianlong molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT weijie molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT yangxue molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT shenqiuying molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT gongzhicheng molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications
AT yanyuanliang molecularaspectofantitumoreffectsofproteaseinhibitornafamostatmesylateanditsroleinpotentialclinicalapplications